Effect of an immune enhancer, GPI-0100, on vaccination with live attenuated herpes simplex virus (HSV) type 2 or glycoprotein D on genital HSV-2 infections of guinea pigs

Antiviral Res. 2008 Nov;80(2):223-4. doi: 10.1016/j.antiviral.2008.05.011. Epub 2008 Jun 23.

Abstract

These studies were performed to determine the effect of AD-472, an attenuated human herpes simplex virus (HSV) type 2 or HSV-2 glycoprotein D (gD) when combined with an adjuvant, GPI-0100, a semi-synthetic Quillaja Saponin analog in a genital HSV-2 infection in guinea pigs. While animals immunized with either vaccine had reduced clinical disease, GPI-0100 only improved the efficacy of gD and did not affect the efficacy of the live vaccine. Neither vaccine had any therapeutic effect if administered 24 h after viral infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic*
  • Animals
  • Female
  • Guinea Pigs
  • Herpes Genitalis / immunology
  • Herpes Genitalis / prevention & control*
  • Herpes Simplex Virus Vaccines / immunology*
  • Herpesvirus 2, Human / immunology*
  • Humans
  • Saponins / immunology*
  • Vaccination*
  • Vaccines, Attenuated / immunology*
  • Viral Envelope Proteins / immunology*

Substances

  • Adjuvants, Immunologic
  • GPI0100
  • Herpes Simplex Virus Vaccines
  • Saponins
  • Vaccines, Attenuated
  • Viral Envelope Proteins
  • glycoprotein D-herpes simplex virus type 2